Technology

The Apta-DC platform is the world's first original concept and can be easily expandable with fundamental based technology that fuses G-quadruplex aptamers with therapeutic anti-cancer drugs.

In case of cancer, a specific protein called nucleolin is overexpressed on the surface of cancer cells. This unique G-quadruple aptamer developed by our company has excellent binding affinity to nucleolin not effecting the normal cells but selectively penetrates only into cancer cells and inhibits the proliferation of cancer cells (Cytostatic effect). At the same time, the cytotoxic drug enters nucleus again and induces the apoptosis of cancer cells.

As a result of this mechanism, Apta-DC complex can be used for development of various anticancer drugs as a useful technique for developing anticancer drugs that have a strong anti-cancer effect and significantly reduced side effects and overcome drug resistance.